Business Standard

Friday, December 20, 2024 | 05:12 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Piramal Enterprises

Piramal-Bain's IndiaRF invests Rs 550 cr for majority stake in Impresario

Funds will be used by the company to fuel the further expansion of Impresario's business

Piramal-Bain's IndiaRF invests Rs 550 cr for majority stake in Impresario
Updated On : 15 Nov 2022 | 12:00 AM IST

Piramal Enterprises posts net loss of Rs 1,536 cr on higher provisions

PEL has moved Rs 5,888 crore worth of wholesale assets from Stage 1 to Stage 2 as the management believed there could be potential stress from these assets

Piramal Enterprises posts net loss of Rs 1,536 cr on higher provisions
Updated On : 09 Nov 2022 | 11:08 PM IST

Varun Beverages, ABB, Page among six stocks that could become large-caps

They could replace Piramal Enterprises, Gland Pharma, Mphasis, Muthoot Finance, Bandhan Bank and Paytm, which may move to mid-cap space, reveals analysis by Brian Freitas of Periscope Analytics

Varun Beverages, ABB, Page among six stocks that could become large-caps
Updated On : 04 Nov 2022 | 10:26 PM IST

MSCI sets aside Piramal Pharma's exclusion from global standard index

The company was listed separately on October 19, following its demerger from Piramal Enterprises

MSCI sets aside Piramal Pharma's exclusion from global standard index
Updated On : 27 Oct 2022 | 11:33 PM IST

We won't make an acquisition just because we have to: Piramal Pharma chief

In a Q&A, Nandini Piramal, chairperson of the firm, says the company currently sees great scope in expanding and organically growing the OTC business, and wants to build more consumer focused brands

We won't make an acquisition just because we have to: Piramal Pharma chief
Updated On : 20 Oct 2022 | 1:13 AM IST

Piramal Pharma ends at Rs 192 on debut, valued at Rs 22,882 cr at close

Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock

Piramal Pharma ends at Rs 192 on debut, valued at Rs 22,882 cr at close
Updated On : 19 Oct 2022 | 11:16 PM IST

Piramal Enterprises slips 9% to hit 52-week low; stock slumps 11% in 2 days

In the past two days, the stock slipped 11 per cent after the RBI directed M&M Financial Services to immediately cease any recovery or repossession activities via an outsource till further orders.

Piramal Enterprises slips 9% to hit 52-week low; stock slumps 11% in 2 days
Updated On : 26 Sep 2022 | 12:05 PM IST

Stocks to Watch: Central Bank, ITI, M&M, Yes Bank, SpiceJet, PEL, GPT Infra

Stocks to Watch Today: Central Bank of India has removed from the RBI's PCA framework after 5 years; SpiceJet places 80 pilots on leave without pay for three months.

Stocks to Watch: Central Bank, ITI, M&M, Yes Bank, SpiceJet, PEL, GPT Infra
Updated On : 21 Sep 2022 | 7:26 AM IST

Piramal Enterprises shares trade ex-demerger; stock surges 9% intra-day

The record date is fixed as September 01, 2022 for issuance and allotment of 4 equity shares (Rs 10 each) of Piramal Pharma (PPL) for every 1 equity share (Rs 2 each) to shareholders of Piramal Ent

Piramal Enterprises shares trade ex-demerger; stock surges 9% intra-day
Updated On : 30 Aug 2022 | 11:25 AM IST

NCLT approves the demerger of Piramal Enterprises' pharma business

This paves the way towards creation of two sepa­ra­te listed entities - Piramal Enter­prises and Piramal Pharma

NCLT approves the demerger of Piramal Enterprises' pharma business
Updated On : 13 Aug 2022 | 12:44 AM IST

NCLT okays demerger plan of Piramal Enterprises into pharma, corporate biz

"We are on track to achieve the completion of demerger and separate listing of Piramal Pharma by the third quarter of the current financial year," PEL Chairperson Ajay Piramal said.

NCLT okays demerger plan of Piramal Enterprises into pharma, corporate biz
Updated On : 12 Aug 2022 | 10:38 PM IST

Pharma companies with quality compliance to be stronger: Piramal

Pharmaceutical businesses that have a strong track record of quality compliance and can remain agile towards new regulatory requirements, will emerge stronger as the impact of the pandemic decreases, according to Piramal Enterprises Ltd Chairman Ajay G Piramal. Addressing shareholders in the company's annual report for 2021-22, Piramal said the company's pharma vertical is expected to have nearly 15 per cent CAGR revenue growth across businesses in the medium to long-term. "In the current circumstances, the pharmaceutical sector has emerged as an essential industry, with an ever-more critical role in today's evolving world," he wrote. Stating that the world's economy and infrastructure continue to be affected by significant supply chain disruptions and volatility in raw material costs, Piramal said safeguarding the supply chain is extremely critical and the company's teams have been pro-actively working towards diversifying vendor base and obtaining alternative suppliers to reduce .

Pharma companies with quality compliance to be stronger: Piramal
Updated On : 09 Jul 2022 | 2:54 AM IST

Ahead of demerger, Piramal Pharma inducts three new board members

Piramal Enterprises has received shareholders' approval to demerge its Piramal Pharma business and simplify the corporate structure

Ahead of demerger, Piramal Pharma inducts three new board members
Updated On : 07 Jul 2022 | 5:33 PM IST

Sensex adds 428 pts, Nifty ends near 16,150; PSBs, OMCs rally; RIL down 1%

CLOSING BELL: It was, largely, a broad-based rally where the Nifty PSU Bank index advanced the most, up 3.4 per cent

Sensex adds 428 pts, Nifty ends near 16,150; PSBs, OMCs rally; RIL down 1%
Updated On : 07 Jul 2022 | 3:37 PM IST

Piramal Enterprises gets shareholders' nod to demerge pharma business

The company has received 99 per cent of votes at the shareholders meeting held on Tuesday, PEL said in a statement

Piramal Enterprises gets shareholders' nod to demerge pharma business
Updated On : 07 Jul 2022 | 12:14 AM IST

Piramal Enterprises dips 10%, hits 52-week low post March quarter results

The stock has fallen below its previous low of Rs 1,688, touched on May 27, 2021

Piramal Enterprises dips 10%, hits 52-week low post March quarter results
Updated On : 27 May 2022 | 11:06 AM IST

Piramal Enterprises logs Rs 151 cr net profit in Q4, overcomes loss

Board recommends a dividend of Rs 33 per share, subject to shareholder's approval.

Piramal Enterprises logs Rs 151 cr net profit in Q4, overcomes loss
Updated On : 27 May 2022 | 1:10 AM IST

Piramal Capital & Housing Finance to hire 6k, to increase branches to 400

At present, the PCHFL has a loan book of around Rs. 2,100 crore in UP, and 21 branches covering all the key markets in the state

Piramal Capital & Housing Finance to hire 6k, to increase branches to 400
Updated On : 06 May 2022 | 12:20 AM IST

Piramal Enterprises gets board nod to raise up to Rs 700 cr through bonds

The committee in its meeting held on Wednesday approved the issuance of the NCDs on private placement basis, Piramal Enterprises said in a regulatory filing

Piramal Enterprises gets board nod to raise up to Rs 700 cr through bonds
Updated On : 04 May 2022 | 11:17 AM IST

Piramal Enterprises plans to raise up to Rs 700 crore through bonds

A meeting of the administrative committee of the board of directors of the company will be held on May 4, 2022, to consider and approve the issuance of NCDs for up to Rs 50 crore

Piramal Enterprises plans to raise up to Rs 700 crore through bonds
Updated On : 28 Apr 2022 | 8:54 PM IST